What happened
MAR001 trial evaluates ANGPTL4 inhibition for elevated triglycerides and remnant cholesterol, with results pending.
Why the trial, key points, tables, limitations, PICO, abstract, media & sources
Expert reaction
AHA Scientific Sessions 2026
0 experts have reacted so far. We show the split once 3 have.
Expert labels are toward TYDAL-TIMI 78's result, from named public quotes (n=0). As of Oct 23, 2026.
A randomized trial of ANGPTL4 inhibition with MAR001 in adults with elevated triglycerides and remnant cholesterol concentrations (TYDAL-TIMI 78)
A randomized trial of ANGPTL4 inhibition with MAR001 in adults with elevated triglycerides and remnant cholesterol concentrations (TYDAL-TIMI 78). Session: LBS.05. Late-breaking trial at AHA Scientific Sessions 2026. Results pending.
No takes yet. Share an insight, caveat, or question.
Chung et al. (2026) studied this question. ANGPTL4 inhibition with MAR001 is being evaluated in a randomized trial for adults with elevated triglycerides and remnant cholesterol, with results currently pending.